

DAFTAR PUSTAKA

- Alicic RZ, Rooney MT, Tuttle KR, 2017, Diabetic Kidney Disease: Challenges, Progress, and Possibilities, *Clin J Am Soc Nephrol*, 12(12):2032-2045, doi: 10.2215/CJN.11491116.
- Ahmad NS, Islahudin F, Paraidathathu T, 2014, Factors associated with good glycemic control among patients with type 2 diabetes mellitus, *J Diabetes Investig*, 5(5):563-9, doi: 10.1111/jdi.12175.
- Amanda Anggraini, Tri Murti Andayani, Zullies Ikawati, 2023, Perbandingan Efektivitas Glikuidon dengan Insulin pada Pengobatan Diabetes Pasien Penyakit Ginjal Kronik, *Majalah Farmaseutik*, 19(2):230-236.
- American Diabetes Association (ADA), 2021, Standards of Medical Care in Diabetes 2021 Abridged for Primary Care Providers. *Clin Diabetes*, 39(1): 14-43.
- American Diabetes Association (ADA), 2022, Standards of Medical Care in Diabetes 2022 Abridged for Primary Care Providers. *Clin Diabetes*, 40 (1): 10-38.
- American Diabetes Association (ADA), 2023, Classification and Diagnosis of Diabetes: Standards of Care in Diabetes 2023, *Diabetes Care*, 46 (Supplement_1): S19-S40.
- American Diabetes Association (ADA), 2024, Diagnosis and Classification of Diabetes: Standards of Care in Diabetes 2024. *Diabetes Care*, 47 (Supplement_1): S20-S42
- American Diabetes Association (ADA), 2024, Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes 2024, *Diabetes Care*, 47 (Supplement_1): S158-S178.
- American Diabetes Association (ADA), 2024, Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes 2024, *Diabetes Care*, 47 (Supplement_1): S111-S125.
- Arnouts P, Bolignano D, Nistor I, Bilo H, Gnudi L, Heaf J, van Biesen W., 2014, Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties, *Nephrol Dial Transplant*, 29(7):1284-300, doi: 10.1093/ndt/gft462.
- Barrot-de la Puente J, Mata-Cases M, Franch-Nadal J, Mundet-Tudurí X, Casellas A, Fernandez-Real JM, Mauricio D., 2015, Older type 2 diabetic patients are more likely to achieve glycaemic and cardiovascular risk factors targets than younger patients: analysis of a primary care database, *Int J Clin Pract*, 69(12):1486-95, doi: 10.1111/ijcp.12741.
- Betônico CC, Titan SM, Correa-Giannella ML, Nery M, Queiroz M., 2016, Management of diabetes mellitus in individuals with chronic kidney

- disease: therapeutic perspectives and glycemic control, *Clinics (Sao Paulo)*, 71(1):47-53, doi: 10.6061/clinics/2016(01)08.
- Bin Rakhis SA Sr, AlDuwayhis NM, Aleid N, AlBarrak AN, Aloraini AA., 2022, Glycemic Control for Type 2 Diabetes Mellitus Patients: A Systematic Review, *Cureus*, 14(6):26180.
- Brown A, Reynolds LR, Bruemmer D, 2010, Intensive glycemic control and cardiovascular disease: an update, *Nat Rev Cardiol*, 7(7):369-75.
- Cao H, Liu T, Wang L, Ji Q., 2022, Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis. *Diabetes Obes Metab*, 24(8):1448-1457, doi:10.1111/dom.14702.
- Carrero JJ, Hecking M, Chesnaye NC, Jager KJ., 2018, Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. *Nat Rev Nephrol.*, 14(3):151-164., doi: 10.1038/nrneph.2017.181.
- Centers for Disease Control and Prevention, 2023, *Chronic Kidney Disease in the United States*, Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention.
- Centers for Disease Control and Prevention, 2023, *Chronic Kidney Disease*, Chronic Kidney Disease | Diabetes | CDC, 10 September 2024.
- Centers for Disease Control and Prevention, 2024, *Diabetes*, Diabetes Basics | Diabetes | CDC, 12 September 2024.
- Cheng LJ, Wang W, Lim ST, Wu VX., 2019, Factors associated with glycaemic control in patients with diabetes mellitus: A systematic literature review, *J Clin Nurs*, 28(9-10):1433-1450, doi: 10.1111/jocn.14795.
- Chieh-Li Yen, Chao-Yi Wu, Lai-Chu See, Yi-Jung Li, Min-Hua Tseng, Wei-Sheng Peng, Jia-Rou Liu, Yung-Chang Chen, Tzung-Hai Yen, Ya-Chung Tian, Chih-Wei Yang, Gerard F. Anderson, Huang-Yu Yang, 2020, Pioglitazone Reduces Mortality and Adverse Events in Patients With Type 2 Diabetes and With Advanced Chronic Kidney Disease: National Cohort Study. *Diabetes Care*, 43 (10): e152–e153. <https://doi.org/10.2337/dc20-1584>.
- De Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, Rosas SE, Rossing P, Bakris G., 2022, Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO), *Diabetes Care*, 45(12):3075-3090.
- DiNicolantonio JJ, Bhutani J, O'Keefe JH, 2015, Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes, *Open Heart*, 2(1):e000327, doi: 10.1136/openhrt-2015-000327.

- DiPiro, J. T., Yee, G. C., & Posey, L. M., 2020, *Pharmacotherapy A Pathophysiologic Approach Eleventh Edition*, McGraw-Hill Professional, New York.
- DiPiro J.T, Gary C. Yee, Stuart T. Haines, Thomas D. Nolin, Vicki Ellingrod, L. Michael Posey., 2023, *DiPiro's Pharmacotherapy: A Pathophysiologic Approach*, 12th Edition, McGraw-Hill Professional, New York.
- Donabedian A, 2005, Evaluating the quality of medical care, *Milbank Q*, 83(4):691-729, doi: 10.1111/j.1468-0009.2005.00397.
- Du YF, Ou HY, Beverly EA, Chiu CJ., 2014, Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options, *Clin Interv Aging*, 9:1963-80, doi: 10.2147/CIA.S53482. PMID: 25429208; PMCID: PMC4241951.
- Farmaki P, Damaskos C, Garmpi N, Garmpi A, Savvanis S, Diamantis E., 2020, Complications of the Type 2 Diabetes Mellitus, *Curr Cardiol Rev*, 16(4):249-251.
- Galindo RJ, Beck RW, Scioscia MF, Umpierrez GE, Tuttle KR., 2020, Glycemic Monitoring and Management in Advanced Chronic Kidney Disease, *Endocr Rev*, 41(5):756–74, doi: 10.1210/edrev/bnaa017.
- G Duarte F, da Silva Moreira S, Almeida MDCC, de Souza Teles CA, Andrade CS, Reingold AL, Moreira ED Jr., 2019, Sex differences and correlates of poor glycaemic control in type 2 diabetes: a cross-sectional study in Brazil and Venezuela, *BMJ Open*, 9(3):e023401, doi: 10.1136/bmjopen-2018-023401.
- Global Burden of Disease Collaborative Network, 2020, *Global Burden of Disease Study 2019 Results*, Institute for Health Metrics and Evaluation, www.who.int/news-room/fact-sheets/detail/diabetes, 20 Juli 2024.
- Hahr AJ, Molitch ME., 2015, Management of diabetes mellitus in patients with chronic kidney disease, *Clin Diabetes Endocrinol*, 1:2. doi: 10.1186/s40842-015-0001-9.
- Heald AH, Stedman M, Davies M, Livingston M, Alshames R, Lunt M, Rayman G, Gadsby R., 2020, Estimating life years lost to diabetes: outcomes from analysis of National Diabetes Audit and Office of National Statistics data. *Cardiovasc Endocrinol Metab*, 9(4): 183-185.
- Hermansen K, Mortensen LS, Hermansen ML., 2008, Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease, *Vasc Health Risk Manag*, 4(3):561-74, doi: 10.2147/vhrm.s1815.
- Ho CC, Yang YS, Huang CN, Lo SC, Wang YH, Kornelius E., 2022, The efficacy of pioglitazone for renal protection in diabetic kidney disease, *PLoS One*, 17(2):e0264129. doi: 10.1371/journal.pone.0264129.

- Huri HZ, Lim LP, Lim SK., 2015, Glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with renal complications, *Drug Des Devel Ther*, 9:4355-4371.
- International Diabetes Federation, 2021, *IDF Diabetes Atlas*, 10th edn, International Diabetes Federation, Brussels.
- Kautzky-Willer A, Harreiter J, Pacini G., 2016, Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. *Endocr Rev.*, (3):278-316. doi: 10.1210/er.2015-1137.
- Kementerian Kesehatan Republik Indonesia, 2016, *Peraturan Menteri Kesehatan Republik Indonesia Nomor 25 Tahun 2016 tentang Rencana Aksi Nasional Kesehatan Lanjut Usia Tahun 2016-2019*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementerian Kesehatan Republik Indonesia, 2018, *Riset Kesehatan Dasar (RISKESDAS) 2018*, Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementerian Kesehatan Republik Indonesia, 2023, *Survei Kesehatan Indonesia (SKI) 2023*, Badan Kebijakan Pembangunan Kesehatan Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kidney Disease Improving Global Outcome, 2022, KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease, *Kidney International Supplement*, 102 (Supplement 5S): S1-S127.
- Kidney Disease Improving Global Outcome, 2024, KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, *Kidney International Supplement*, 105 (Supplement 4S): S117-S314.
- Kovesdy, C. P., 2022, Epidemiology of chronic kidney disease: an update 2022. Dalam *Kidney International Supplements*, Elsevier B.V., 12(1):7–11, <https://doi.org/10.1016/j.kisu.2021.11.003>.
- Lee WC, Lee YT, Li LC, Ng HY, Kuo WH, Lin PT, Liao YC, Chiou TT, Lee CT., 2018, The Number of Comorbidities Predicts Renal Outcomes in Patients with Stage 3-5 Chronic Kidney Disease, *J Clin Med*, 7(12):493. doi: 10.3390/jcm7120493.
- Ley SH, Schulze MB, Hivert MF, Meigs JB, Hu FB., 2018, *Diabetes in America: Risk Factors for Type 2 Diabetes*, 3rd ed, Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, US.
- Luijckx H, Biermans M, Bor H, van Weel C, Lagro-Janssen T, de Grauw W, Schermer T., 2015, The Effect of Comorbidity on Glycemic Control and Systolic Blood Pressure in Type 2 Diabetes: A Cohort Study with 5 Year Follow-Up in Primary Care, *PLoS One*, 10(10):e0138662, doi: 10.1371/journal.pone.0138662.

- Mouri MI, Badireddy M., 2023, *Hyperglycemia.*, <https://www.ncbi.nlm.nih.gov/books/NBK430900/>, 16 September 2024.
- Nathan DM, Zinman B, Patricia A *et al.*, 2009, Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). *Arch Intern Med*, 169(14):1307-1316. doi:10.1001/archinternmed.2009.193.
- National Kidney Foundation, 2025, *Kidney Failure Risk Factor: Gender (Sex)*, Diakses melalui <https://www.kidney.org/kidney-failure-risk-factor-gender-sex> pada 7 Januari 2025.
- Nanayakkara N, Ranasinha S, Gadowski AM, Davis WA, Flack JR, Wischer N, Andrikopoulos S, Zoungas S, 2018, Age-related differences in glycaemic control, cardiovascular disease risk factors and treatment in patients with type 2 diabetes: a cross-sectional study from the Australian National Diabetes Audit, *BMJ Open*, 8(8):e020677, doi: 10.1136/bmjopen-2017-020677.
- Neumiller JJ, Alicic RZ, Tuttle KR., 2017, Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease. *J Am Soc Nephrol*, 28(8):2263-2274.
- Nordheim E, Geir Jenssen T., 2021, Chronic kidney disease in patients with diabetes mellitus, *Endocr Connect*, 10(5):R151-R159.
- Noronha IL, Santa-Catharina GP, Andrade L, Coelho VA, Jacob-Filho W, Elias RM., 2022, Glomerular filtration in the aging population, *Front Med (Lausanne)*, 9:769329. doi: 10.3389/fmed.2022.769329.
- Oguz A, Benroubi M, Brismar K, Melo P, Morar C, Cleall SP, Giaconia J, Schmitt H., 2013, Clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes in five countries: results from the TREAT study, *Curr Med Res Opin*, 29(8):911-20, doi: 10.1185/03007995.2013.803053.
- Oktaviani, E., Indriani, L., Emma N P K, Futriani, 2021, Kontrol Glikemik dan Profil Serum Kreatinin Pada Pasien DM Tipe 2 Dengan Gagal Ginjal Kronik, *JMPF*, 11(2):100-113.
- Pearl G. Lee dan Jeffrey B. Halter, 2017, The Pathophysiology of Hyperglycemia in Older Adults: Clinical Considerations, *Diabetes Care*, 40 (4): 444–452, <https://doi.org/10.2337/dc16-1732>
- Perhimpunan Nefrologi Indonesia, 2023, *13th annual report of in Indonesian Renal Registry (IRR) pada tahun 2020*, Jakarta.
- Perkumpulan Endokrinologi Indonesia (Perkeni), 2019, *Pedoman Terapi Insulin Pada Pasien Diabetes Melitus*, Jakarta, hal 3-21.

- Perkumpulan Endokrinologi Indonesia (Perkeni), 2021, *Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia*, Jakarta.
- Perkumpulan Endokrinologi Indonesia (Perkeni), 2021, *Pedoman Petunjuk Praktis Terapi Insulin Pada Pasien Diabetes Melitus*, Jakarta, hal 3-21.
- Pontremoli R, Bellizzi V, Bianchi S, et al, 2020, Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology, *J Nephrol*, 33(3):417-430. doi:10.1007/s40620-020-00707-2
- Punthakee, Z., Goldenberg, R., Katz, P., 2018, Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome, *Canadian Journal of Diabetes*, 42: S10–S15.
- Rahman MS, Hossain KS, Das S, Kundu S, Adegoke EO, Rahman MA, Hannan MA, Uddin MJ, Pang MG, 2021, Role of Insulin in Health and Disease: An Update, *Int J Mol Sci*, 22(12):6403, doi: 10.3390/ijms22126403.
- Ratnasari P.M.D, Tri Murti A, Dwi Endarti., 2019, Analisis Luaran Klinik Pasien Diabetes Melitus Tipe 2 Berdasarkan Peresepan Antidiabetik dan Komplikasi, *Majalah Farmaseutik*, 16(2):163-169.
- Raveendran AV, Chacko EC, Pappachan JM., 2018, Non-pharmacological Treatment Options in the Management of Diabetes Mellitus, *Eur Endocrinol*, 14(2):31-39.
- Retta C Sihotang, Rizka Ramadhani, Dicky L. Tahapary, 2018, Efikasi dan Keamanan Obat Anti Diabetik Oral pada Pasien Diabetes Melitus Tipe 2 dengan Penyakit Ginjal Kronik, *Jurnal Penyakit Dalam Indonesia*, 5(3):151-155.
- Rini S, Hadisaputro S, Hs HN, Budijitno S, 2018, Faktor Risiko Penyakit Ginjal Kronik Diabetes (PGK-DM) pada Diabetes Mellitus Tipe-2 (Studi di RSUD DR Soedarso Kota Pontianak Provinsi Kalimantan Barat), *Jurnal Epidemiologi Kesehatan Komunitas*.
- Rita R. Kalyani, Sherita H. Golden, William T. Cefalu, 2017, Diabetes and Aging: Unique Considerations and Goals of Care, *Diabetes Care*, 40 (4): 440–443. <https://doi.org/10.2337/dci17-0005>
- Sapra A dan Bhandari P., 2023, *Diabetes*, <https://www.ncbi.nlm.nih.gov/books/NBK551501/>, 1 September 2024.
- Shamshirgaran SM, Mamaghanian A, Aliasgarzadeh A, Aiminisani N, Iranparvar-Alamdari M, Ataie J., 2017, Age differences in diabetes-related complications and glycemic control, *BMC Endocr Disord*, 17(1):25, doi: 10.1186/s12902-017-0175-5.
- Shukla UV dan Tripathy K., 2023, *Diabetic Retinopathy*, <https://www.ncbi.nlm.nih.gov/books/NBK560805/>, 12 September 2024.

- Siddiqui K, George TP, Joy SS, Alfadda AA., 2022, Risk factors of chronic kidney disease among type 2 diabetic patients with longer duration of diabetes, *Front Endocrinol (Lausanne)*, 13:1079725.
- Sukwika, T., 2023, Menentukan Populasi dan Sampling. *Metode Penelitian (Dasar Praktik dan Penerapan Berbasis ICT)*. 159-17.
- Sulaiman MK, 2019, Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management, *Diabetol Metab Syndr*, 11:7.
- Thota S dan Akbar A., 2023, *Insulin*, Diakses melalui <https://www.ncbi.nlm.nih.gov/books/NBK560688/>, 11 September 2024.
- Trevisan R., 2017, The Role of Vildagliptin in the Therapy of Type 2 Diabetic Patients with Renal Dysfunction, *Diabetes Ther*, 8(6):1215-1226, doi: 10.1007/s13300-017-0302-3.
- Trionzi JL, Parker Gregg L, Virani SS, Navaneethan SD., 2021, Management of type 2 diabetes in chronic kidney disease, *BMJ Open Diabetes Res Care*, 9(1):e002300. doi: 10.1136/bmjdr-2021-002300.
- Tsai WC, Wu HY, Peng YS, Ko MJ, Wu MS, Hung KY, Wu KD, Chu TS, Chien KL., 2016, Risk Factors for Development and Progression of Chronic Kidney Disease: A Systematic Review and Exploratory Meta-Analysis, *Medicine (Baltimore)*, 95(11):3013.
- Vaidya SR dan Aeddula NR., 2024, *Chronic Kidney Disease*, <https://www.ncbi.nlm.nih.gov/books/NBK535404/>, 17 September 2024.
- Vijan S, 2010, In the clinic. Type 2 diabetes, *Ann Intern Med*, 2(5):152.
- WHO, 2016, *Global Report On Diabetes*, Global report on diabetes (who.int), 23 Juli 2024.
- Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME, Hamet P, Harrap S, Heller S, MacMahon S, Mancia G, Marre M, Matthews D, Neal B, Poulter N, Rodgers A, Williams B, Zoungas., 2016, Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON, *Diabetes Care*, 39(5):694-700.
- Wilson S, Mone P, Jankauskas SS, Gambardella J, Santulli G., 2021, Chronic kidney disease: Definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk, *J Clin Hypertens (Greenwich)*, (4):831-834.
- Xie X, Wu C, Hao Y, Wang T, Yang Y, Cai P, Zhang Y, Huang J, Deng K, Yan D and Lin H., 2023, Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review, *Front. Endocrinol*, 14:1301093.
- Yu MG, Gordin D, Fu J, Park K, Li Q, King GL., 2024, Protective Factors and the Pathogenesis of Complications in Diabetes, *Endocr Rev*, 45(2):227-252.